专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009022354A3 MODIFIED DOSAGE FORMS OF TACROLIMUS 审中-公开
标题翻译：改良剂量剂型
公开(公告)号：WO2009022354A3
公开(公告)日：2009-04-09
申请号：PCT/IN2008000179
申请日：2008-03-25
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , SINGH SARABJIT , PUTHLI SHIVANAND , JAIN RAJESH
发明人： SINGH AMARJIT , SINGH SARABJIT , PUTHLI SHIVANAND , JAIN RAJESH
IPC分类号： A61K31/4745 , A61K9/22
CPC分类号： A61K9/146 , A61K9/1676 , A61K9/5078 , A61K9/5084 , A61K31/436
摘要： The present invention provides a modified release dosage form of tacrolimus that releases two or more amount of tacrolimus upon oral administration, the first amount of tacrolimus releases from the immediate release dosage unit substantially immediately within 0-2 hours followed by a time interval ranging from about 1-10 hours during which substantially no amount of tacrolimus is released from the dosage form, after which a second amount of tacrolimus is released wherein said second amount is released from the delayed release dosage unit either immediately e.g. within 0-2 hours or over a period of time ranging from about 2-12 hours from its initial release from the delayed release dosage unit. The dosage form may further comprise additional amount of tacrolimus to provide additional pulse of tacrolimus. The dosage forms of tacrolimus exhibit improved bioavailability and reduced flux or fluctuation over existing composition of tacrolimus. A method of preparing the dosage forms is also described.
摘要翻译：本发明提供了他克莫司的释放剂型，其口服给药释放两种或更多量的他克莫司，第一批量的他克莫司基本上立即在0-2小时内立即从立即释放剂量单位释放，之后是从约 1-10小时，其中基本上没有量的他克莫司从剂型中释放出来，之后第二量的他克莫司被释放，其中所述第二量从延迟释放剂量单位释放，在0-2小时内或超过延迟释放剂量单位从其初始释放约2-12小时的时间段内。剂型还可包含额外量的他克莫司以提供他克莫司的额外脉冲。他克莫司的剂型表现出改善的生物利用度和减少通量或波动超过现有组合的他克莫司。还描述了制备剂型的方法。

2. 发明申请

WO2012035559A3 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING PREGABALIN 审中-公开
标题翻译：包含PREGABALIN的持续释放药物组合物
公开(公告)号：WO2012035559A3
公开(公告)日：2012-06-28
申请号：PCT/IN2011000638
申请日：2011-09-15
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , SINGH SARABJIT , PUTHLI SHIVANAND
发明人： JAIN RAJESH , SINGH SARABJIT , PUTHLI SHIVANAND
IPC分类号： A01N37/12 , A61K31/195
CPC分类号： A61K9/0002 , A61K9/1623 , A61K9/2018 , A61K9/2054 , A61K31/197 , A61K47/26
摘要： The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.
摘要翻译：本发明涉及稳定的每日缓释药物组合物，其包含普瑞巴林或其药学上可接受的盐和药学上可接受的赋形剂，其中药物组合物与普瑞巴林的常规速释制剂每天施用两次是生物等效的。本发明进一步涉及包含普瑞巴林和糖酯作为用于维持药物的均匀释放速率的释放延缓剂的组合物以及制备这种口服缓释制剂的方法。

3. 发明申请

WO2010082214A2 FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY 审中-公开
标题翻译：具有增强口腔生物利用度的FENOFIBRATE配方
公开(公告)号：WO2010082214A2
公开(公告)日：2010-07-22
申请号：PCT/IN2009000365
申请日：2009-06-26
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , SINGH SARABJIT , JAIN NAVEEN , PUTHLI SHIVANAND
发明人： JAIN RAJESH , SINGH SARABJIT , JAIN NAVEEN , PUTHLI SHIVANAND
IPC分类号： A61K9/48 , A61K31/216
CPC分类号： A61K9/4858
摘要： The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.
摘要翻译：本发明提供了非诺贝特的制剂，其具有增强的口服生物利用度，设计和制造的简单性和食物效果的不存在。该制剂包含溶解在亲脂性表面活性剂中的非诺贝特，任选加入亲水性表面活性剂。该制剂可以有效地用于治疗和治疗诸如高甘油三酯血症，高胆固醇血症和混合性血脂异常的病症，并且与可商购的产品相比也可以以较低的剂量有效。本发明还涉及制剂的制备方法和包含其的剂型。

4. 发明申请

WO2009050726A3 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF BUPROPION 审中-公开
标题翻译：用于改进交付运输的组合物和方法
公开(公告)号：WO2009050726A3
公开(公告)日：2009-06-25
申请号：PCT/IN2008000337
申请日：2008-05-28
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , SINGH SARABJIT , PRASAD KORLAKUNTE , JAIN RAJESH
发明人： SINGH AMARJIT , SINGH SARABJIT , PRASAD KORLAKUNTE , JAIN RAJESH
IPC分类号： A61K9/50 , A61K9/16 , A61K31/137
CPC分类号： A61K31/137 , A61K9/0043 , A61K9/141 , A61K9/48 , A61K9/5021
摘要： The present invention provides a pharmaceutical composition comprising micronized bupropion having controlled particle size in the range between 1-60 µm. The pharmaceutical composition of the present invention comprises micronized bupropion having median particle size less than 40 micron, which exhibits outstanding bioavailability via nasal and pulmonary route even without any need for blending the micronized bupropion with large carrier particles. The composition of the present invention comprises micronized bupropion -and one or more pharmaceutically acceptable carriers, surfactants, a dispersing agents, or dispersants, which can be administered in an aerosol formulation as a dry powder for nasal and pulmonary inhalation. Particularly, the composition of the present invention for nasal delivery comprises bioadhesive microparticles of bupropion and carbohydrates like pullulan to prevent and treat diseases such as depression, premenstrual syndrome, premature ejaculation and as an aid to smoking cessation. The invention also provides a process of preparing the compositions of the present invention.
摘要翻译：本发明提供一种药物组合物，其包含微粒化的安非他酮，其控制粒度在1-60μm之间。本发明的药物组合物包含中值粒度小于40微米的微粉化安非他酮，即使不需要将微粉化的安非他酮与大载体颗粒混合，也可以通过鼻和肺途径表现出优异的生物利用度。本发明的组合物包含微粉化的安非他酮和一种或多种药学上可接受的载体，表面活性剂，分散剂或分散剂，其可以作为用于鼻吸入和肺部吸入的干粉在气溶胶制剂中施用。特别地，用于鼻腔输送的本发明的组合物包括安非他酮的生物粘附微粒和诸如支链淀粉的碳水化合物，以预防和治疗诸如抑郁症，经前期综合征，早泄以及作为戒烟的辅助之类的疾病。本发明还提供了制备本发明组合物的方法。

5. 发明申请

WO2008062429A3 PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF 审中-公开
标题翻译：用于递送活性成分的颗粒，其制备方法和组合物
公开(公告)号：WO2008062429A3
公开(公告)日：2008-11-13
申请号：PCT/IN2007000340
申请日：2007-08-10
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , SINGH SARABJIT , SINGH PARAMJIT , JAIN RAJESH
发明人： SINGH AMARJIT , SINGH SARABJIT , SINGH PARAMJIT , JAIN RAJESH
IPC分类号： B82B3/00 , A61K9/00 , A61K9/51 , A61K47/30
CPC分类号： A61K9/19 , A61K9/5115 , A61K9/5161 , A61K9/5192 , B82Y5/00
摘要： The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.
摘要翻译：本发明公开了具有包含无机元素的颗粒的组合物; 一种或多种活性成分和任选的释放速度调节剂，其适用于将活性成分递送至人和动物组织。颗粒是纳米颗粒或微颗粒或其混合物，优选通过溶胶 - 凝胶方法制备。该组合物可用于局部或粘膜表面，优选以霜剂，凝胶剂，洗剂，干粉剂，喷雾剂，泡沫剂和其它合适的形式施用。

6. 发明申请

WO2010106557A3 STABLE PHARMACEUTICAL FORMULATIONS COMPRISING ANHYDROUS LANTHANUM CARBONATE AND PROCESS FOR PREPARATION THEREOF 审中-公开
标题翻译：包含无机碳酸锰的稳定药物制剂及其制备方法
公开(公告)号：WO2010106557A3
公开(公告)日：2011-03-10
申请号：PCT/IN2010000163
申请日：2010-03-19
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , SINGH SARABJIT , SINGH PARAMJIT , SINGH PIRTHI PAL
发明人： JAIN RAJESH , SINGH SARABJIT , SINGH PARAMJIT , SINGH PIRTHI PAL
IPC分类号： A01N59/16 , A61K33/24
CPC分类号： A61K33/24 , A61K9/0056 , A61K9/2054
摘要： The present invention discloses the premix pharmaceutical formulation comprising anhydrous lanthanum carbonate. The present invention further relates to a stable pharmaceutical formulation comprising a therapeutically effective amount of anhydrous lanthanum carbonate and pharmaceutically acceptable carrier and/or excipients, with the proviso that the said formulation is substantially free of monosaccharides or disaccharides. Further the said formulation is substantially free of amino acids and/or stabilizers. The process of preparing such formulations is also described.
摘要翻译：本发明公开了包含无水碳酸镧的预混药物制剂。本发明还涉及包含治疗有效量的无水碳酸镧和药学上可接受的载体和/或赋形剂的稳定药物制剂，条件是所述制剂基本上不含单糖或二糖。此外，所述制剂基本上不含氨基酸和/或稳定剂。还描述了制备这种制剂的方法。

7. 发明申请

WO0122917A3 EFFERVESCENT COMPOSITIONS COMPRISING NIMESULIDE 审中-公开
标题翻译：含有NIMESULIDE的高效组合物
公开(公告)号：WO0122917A3
公开(公告)日：2001-12-27
申请号：PCT/IN0000093
申请日：2000-09-27
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , JAIN RAJESH
发明人： SINGH AMARJIT , JAIN RAJESH
IPC分类号： A61K9/32 , A61K9/36 , A61K9/46 , A61K31/18 , A61K9/20 , A61K9/28
CPC分类号： A61K31/18 , A61K9/0007
摘要： An effervescent Pharmaceutical composition comprising the drug Nimesulide, one or more acids and one or more carbonate source wherein the ratio between Nimesulide and the total carbonate source is between 1:17 to 1:2 w/w.
摘要翻译：泡腾药物组合物，其包含药物尼美舒利，一种或多种酸和一种或多种碳酸酯源，其中尼美舒利与总碳酸酯源之比为1:17至1:2w / w。

8. 发明申请

WO0042987A3 TARGETED VESICULAR CONSTRUCTS FOR CYTOPROTECTION AND TREATMENT OF H. PYLORI INFECTIONS 审中-公开
标题翻译：靶向幽门螺杆菌感染的细胞构建及治疗
公开(公告)号：WO0042987A3
公开(公告)日：2000-11-02
申请号：PCT/IN0000004
申请日：2000-01-24
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , JAIN RAJESH
发明人： SINGH AMARJIT , JAIN RAJESH
IPC分类号： A61K47/44 , A61K9/127 , A61K31/341 , A61K31/4164 , A61K31/43 , A61K31/4439 , A61K31/65 , A61K31/7048 , A61K33/24 , A61K45/00 , A61K47/28 , A61K47/42 , A61P1/04 , A61P31/04
CPC分类号： A61K9/1271
摘要： A novel composition for targeted vesicular constructs for treatment of H. pylori infections and for protection of the cell is disclosed. The composition comprises lectins, phospholipids sterols and one or more drugs. The composition is useful since not only it treats h. pylori infections and other diseases associated therewith but also helps in protection of the cell walls.
摘要翻译：公开了用于治疗幽门螺杆菌感染和保护细胞的靶向泡状构建体的新型组合物。该组合物包含凝集素，磷脂甾醇和一种或多种药物。该组合物是有用的，因为它不仅处理h。幽门感染和与之相关的其他疾病，但也有助于保护细胞壁。

9. 发明申请

WO0042987A8 TARGETED VESICULAR CONSTRUCTS FOR CYTOPROTECTION AND TREATMENT OF H. PYLORI INFECTIONS 审中-公开
标题翻译：用于细菌保护和治疗H.PYLORI感染的目标构造
公开(公告)号：WO0042987A8
公开(公告)日：2001-06-28
申请号：PCT/IN0000004
申请日：2000-01-24
申请人： PANACEA BIOTEC LTD , SINGH AMARJIT , JAIN RAJESH
发明人： SINGH AMARJIT , JAIN RAJESH
IPC分类号： A61K47/44 , A61K9/127 , A61K31/341 , A61K31/4164 , A61K31/43 , A61K31/4439 , A61K31/65 , A61K31/7048 , A61K33/24 , A61K45/00 , A61K47/28 , A61K47/42 , A61P1/04 , A61P31/04
CPC分类号： A61K9/1271
摘要： A novel composition for targeted vesicular constructs for treatment of H. pylori infections and for protection of the cell is disclosed. The composition comprises lectins, phospholipids sterols and one or more drugs. The composition is useful since not only it treats h. pylori infections and other diseases associated therewith but also helps in protection of the cell walls.
摘要翻译：公开了用于治疗幽门螺杆菌感染和保护细胞的靶向囊泡构建体的新型组合物。组合物包含凝集素，磷脂甾醇和一种或多种药物。组合是有用的，因为它不仅治疗h。幽门螺杆菌感染和与之相关的其它疾病，但也有助于细胞壁的保护。

10. 发明申请

WO2010029571A3 MODIFIED RELEASE RAMIPRIL COMPOSITIONS AND USES THEREOF 审中-公开
标题翻译：改性释放的RAMIPRIL组合物及其用途
公开(公告)号：WO2010029571A3
公开(公告)日：2010-07-01
申请号：PCT/IN2009000428
申请日：2009-07-28
申请人： PANACEA BIOTEC LTD , JAIN RAJESH , SINGH SARABJIT
发明人： JAIN RAJESH , SINGH SARABJIT
IPC分类号： A61K9/22 , A61K31/403
CPC分类号： A61K9/4808 , A61K9/2009 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K31/403
摘要： The invention relates to a modified release pharmaceutical composition comprising ramipril or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipient(s) wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of ramipril administered twice daily. The invention further relates to a modified release pharmaceutical composition comprising: an immediate release component comprising ramipril or pharmaceutically acceptable salts thereof and a modified release component comprising ramipril or pharmaceutically acceptable salts thereof. The invention further relates to the process for the preparation of modified release pharmaceutical composition of ramipril.
摘要翻译：本发明涉及包含雷米普立或其药学上可接受的盐和药学上可接受的赋形剂的改性释放药物组合物，其中药物组合物与常规立即释放的雷米普利制剂每天两次生物等效。本发明还涉及一种调释释放药物组合物，其包含：包含雷米普里或其药学上可接受的盐的速释组分和包含雷米普利或其药学上可接受的盐的缓释组分。本发明还涉及制备雷米普里缓释药物组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式